Navigation Links
Cancer research brief: Targeting pancreatic cancer drug resistance
Date:7/8/2013

Cold Spring Harbor, NY Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%. Novel therapies are urgently needed, as conventional and targeted approaches have not been successful and drug resistance is an increasing problem.

Previously it had been thought that poor penetration of the drugs into pancreas tumors was the main reason for treatment failure. But now a team of scientists led by Cold Spring Harbor Laboratory (CSHL) Professor David Tuveson M.D., Ph.D., shows there are other factors at work, too.

In a paper published online today in the Proceedings of the National Academy of Sciences, Dr. Tuveson's group shows that there are survival cues inside the pancreatic tumor mass. Molecules in the milieu around the cancer cells, such as Connective Tissue Growth Factor (CTGF), provide "pro-life" signals that overcome the killing power of chemotherapeutic drugs.

"In addition to drug delivery being a problem, there is also this nurturing aspect that prevents cancer cells responding to the drugs," says Tuveson.

But he and his colleagues may have found a way to prevent this. The antibody FG-3019, a molecule that is now in phase 1/2 clinical investigation as a treatment option for pancreatic cancer, binds to CTGF and prevents it from providing cells with survival cues. Those cues seem to be mediated, at least in part, through a molecule within the cell called XIAP (X-linked inhibitor of apoptosis). XIAP derives its name from its function -- an ability to help keep the cell alive by preventing a process called apoptosis, a form of cellular suicide.

The Tuveson lab used a novel mouse model for pancreatic cancer to test FG-3019. Tumors in mice treated with FG-3019 in combination with the chemotherapeutic drug gemcitabine stopped growing. Inside the tumor there was an increase in the amount of cancer cells dying through apoptosis, which was associated with a decrease in levels of XIAP. Importantly, mice treated with both FG-3019 and gemcitabine also had an increased lifespan.

This suggests that overcoming resistance to medicines in cancer may be possible using combination therapy -- co-administering molecules that help open up the tumor to drugs as well as other molecules that prevent cancer cell survival signals alongside the chemotherapeutics. Both CTGF and XIAP have been shown to be present in human pancreatic cancer tumors so combination therapy using antagonists of either molecule could be a feasible approach, says Tuveson.

There are other compounds that sensitize cancer cells to die, for example, antagonists of Bcl-2 and Bcl-xL, cellular proteins that prevent apoptosis. "These are pro-apoptosis medicines, so it's not impossible to imagine that one could target these types of pathways in cancer cells with drugs. We haven't done those studies yet but that would be the logical progression," says Tuveson, who is the Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL and Director of Research for the Lustgarten Foundation.


'/>"/>

Contact: Edward Brydon
ebrydon@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has ... Dr. Talei has come up with a proprietary technique that he calls the ... that have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will host ... , The two-day conference is focused on advancing scientific knowledge about the aggressive ... and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” ...
(Date:6/23/2017)... , ... June 23, 2017 , ... MD Now ... This is MD Now’s 28th facility overall and marks the urgent care center's eighth ... one mile North of The Falls shopping mall. The new clinic offers a wide ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/5/2017)... CINCINNATI , June 5, 2017 The ... a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Cincinnati Enquirer . Results are based on ... specializing in organizational health and workplace improvement. The survey measures ... ...
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
Breaking Medicine Technology: